Edgestream Partners L.P. Has $2.05 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Edgestream Partners L.P. increased its position in Haemonetics Co. (NYSE:HAEGet Rating) by 56.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,440 shares of the medical instruments supplier’s stock after purchasing an additional 11,354 shares during the quarter. Edgestream Partners L.P. owned approximately 0.06% of Haemonetics worth $2,049,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in Haemonetics by 6.0% in the second quarter. Rhumbline Advisers now owns 157,636 shares of the medical instruments supplier’s stock worth $10,275,000 after purchasing an additional 8,866 shares during the period. Bridgewater Associates LP increased its position in Haemonetics by 10.3% in the second quarter. Bridgewater Associates LP now owns 81,045 shares of the medical instruments supplier’s stock worth $5,283,000 after purchasing an additional 7,552 shares during the period. Trexquant Investment LP increased its position in Haemonetics by 3,604.6% in the second quarter. Trexquant Investment LP now owns 126,439 shares of the medical instruments supplier’s stock worth $8,241,000 after purchasing an additional 123,026 shares during the period. Deutsche Bank AG increased its position in Haemonetics by 2.2% in the second quarter. Deutsche Bank AG now owns 270,016 shares of the medical instruments supplier’s stock worth $17,600,000 after purchasing an additional 5,846 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Haemonetics by 41.4% during the second quarter. Bank of Montreal Can now owns 46,712 shares of the medical instruments supplier’s stock worth $3,057,000 after buying an additional 13,673 shares during the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michelle L. Basil sold 11,448 shares of Haemonetics stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $78.36, for a total transaction of $897,065.28. Following the transaction, the executive vice president now owns 32,635 shares in the company, valued at approximately $2,557,278.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Michelle L. Basil sold 33,798 shares of Haemonetics stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $77.89, for a total value of $2,632,526.22. Following the sale, the executive vice president now owns 35,395 shares of the company’s stock, valued at approximately $2,756,916.55. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michelle L. Basil sold 11,448 shares of Haemonetics stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $78.36, for a total value of $897,065.28. Following the completion of the sale, the executive vice president now directly owns 32,635 shares in the company, valued at approximately $2,557,278.60. The disclosure for this sale can be found here. Insiders have sold 45,713 shares of company stock worth $3,566,256 in the last 90 days. Corporate insiders own 1.65% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. JMP Securities raised their target price on Haemonetics from $90.00 to $105.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 8th. Barrington Research raised their target price on Haemonetics from $88.00 to $94.00 and gave the stock an “outperform” rating in a report on Tuesday, November 8th. Citigroup raised their target price on Haemonetics from $80.00 to $88.00 and gave the stock a “neutral” rating in a report on Tuesday, November 8th. Morgan Stanley raised their target price on Haemonetics from $85.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 8th. Finally, StockNews.com assumed coverage on Haemonetics in a report on Wednesday, October 12th. They set a “buy” rating on the stock. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $96.17.

Haemonetics Trading Up 1.2 %

NYSE:HAE opened at $84.13 on Thursday. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $86.48. The company has a debt-to-equity ratio of 1.04, a current ratio of 2.73 and a quick ratio of 1.76. The stock has a market capitalization of $4.26 billion, a PE ratio of 50.68 and a beta of 0.40. The business’s 50-day simple moving average is $78.56 and its 200-day simple moving average is $70.97.

Haemonetics Company Profile

(Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEGet Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.